The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Tazobactamum     (2R,3S)-3-methyl-4,4,7- trioxo-3-(triazol-1...

Synonyms: CCRIS 2203, SureCN13407281, YTR 830H, LS-149903, LS-187342, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Tazobactam


High impact information on Tazobactam


Chemical compound and disease context of Tazobactam


Biological context of Tazobactam


Anatomical context of Tazobactam

  • From a therapeutic viewpoint, given the concentrations of tazobactam recorded in bile fluid and tissue, the addition of this beta-lactamase inhibitor to piperacillin therapy might be of interest in the management of biliary tract infections, mostly in patients at risk of mixed aerobic-anaerobic infections due to beta-lactamase-producing organisms [19].
  • The mean (+/- standard deviation) rates of penetration into the cerebrospinal fluid (CSF) of infected animals were 6.7 +/- 3.9% for piperacillin given alone and 36.3 +/- 21.9% for tazobactam given alone [18].
  • The mean concentration of tazobactam in the investigated gastrointestinal tissues (appendix, proximal and distal mucosa) exceeded levels in plasma after 1 h, while piperacillin showed a mean penetration into these tissues of 43 and 53% [20].
  • Inflammatory exudate penetration was rapid, and the mean maximum levels of tazobactam attained were 6.4 and 11.3 micrograms/ml when it was given alone or with piperacillin, respectively (P less than 0.06) [21].
  • The concentration ratios of piperacillin/tazobactam were 9.4 +/- 1.8 in cancellous bone tissue and 8.0 +/- 2.2 in cortical bone tissue, which were close to the 8:1 ratio of drugs administered [22].

Associations of Tazobactam with other chemical compounds


Gene context of Tazobactam

  • Tazobactam also had no effect on the accumulation of a key intermediate in the AmpC beta-lactamase induction pathway, 1,6-anhydromurotripeptide, in an ampD mutant strain of E. coli [3].
  • Because of the need for control of beta-lactamase-mediated resistance and the recent development of tazobactam, the author has examined the inhibitors of various beta-lactamases for their effectiveness [27].
  • Although the calvulanic acid combination was more potent, tazobactam was effective for a similar spectrum of resistant gram-negative clinical isolates containing beta-lactamase [28].
  • Organisms with type C beta-lactamase were less susceptible than those with type A enzyme to piperacillin/tazobactam and amoxycillin/tazobactam in disc and MIC tests, and to co-amoxiclav in disc tests only [29].
  • Clavulanate and penam sulphones (sulbactam and tazobactam) were more active against TEM-1 and OXA-1, but were less active against TEM-3 and cephalosporinase (Case) than SYN-1012 [30].

Analytical, diagnostic and therapeutic context of Tazobactam


  1. Antibiotic rotation and development of gram-negative antibiotic resistance. van Loon, H.J., Vriens, M.R., Fluit, A.C., Troelstra, A., van der Werken, C., Verhoef, J., Bonten, M.J. Am. J. Respir. Crit. Care Med. (2005) [Pubmed]
  2. Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species. Gavin, P.J., Suseno, M.T., Thomson, R.B., Gaydos, J.M., Pierson, C.L., Halstead, D.C., Aslanzadeh, J., Brecher, S., Rotstein, C., Brossette, S.E., Peterson, L.R. Antimicrob. Agents Chemother. (2006) [Pubmed]
  3. Mechanism of suppression of piperacillin resistance in enterobacteria by tazobactam. Kadima, T.A., Weiner, J.H. Antimicrob. Agents Chemother. (1997) [Pubmed]
  4. Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections. Perry, C.M., Markham, A. Drugs (1999) [Pubmed]
  5. Tazobactam inactivation of SHV-1 and the inhibitor-resistant Ser130 -->Gly SHV-1 beta-lactamase: insights into the mechanism of inhibition. Pagan-Rodriguez, D., Zhou, X., Simmons, R., Bethel, C.R., Hujer, A.M., Helfand, M.S., Jin, Z., Guo, B., Anderson, V.E., Ng, L.M., Bonomo, R.A. J. Biol. Chem. (2004) [Pubmed]
  6. Understanding resistance to beta-lactams and beta-lactamase inhibitors in the SHV beta-lactamase: lessons from the mutagenesis of SER-130. Helfand, M.S., Bethel, C.R., Hujer, A.M., Hujer, K.M., Anderson, V.E., Bonomo, R.A. J. Biol. Chem. (2003) [Pubmed]
  7. Mechanism of inhibition of the class A beta -lactamases PC1 and TEM-1 by tazobactam. Observation of reaction products by electrospray ionization mass spectrometry. Yang, Y., Janota, K., Tabei, K., Huang, N., Siegel, M.M., Lin, Y.I., Rasmussen, B.A., Shlaes, D.M. J. Biol. Chem. (2000) [Pubmed]
  8. Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease. Johnson, C.A., Halstenson, C.E., Kelloway, J.S., Shapiro, B.E., Zimmerman, S.W., Tonelli, A., Faulkner, R., Dutta, A., Haynes, J., Greene, D.S. Clin. Pharmacol. Ther. (1992) [Pubmed]
  9. Novel Ambler Class A {beta}-Lactamase LAP-1 and Its Association with the Plasmid-Mediated Quinolone Resistance Determinant QnrS1. Poirel, L., Cattoir, V., Soares, A., Soussy, C.J., Nordmann, P. Antimicrob. Agents Chemother. (2007) [Pubmed]
  10. In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains. Higgins, P.G., Wisplinghoff, H., Stefanik, D., Seifert, H. Antimicrob. Agents Chemother. (2004) [Pubmed]
  11. Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Bryson, H.M., Brogden, R.N. Drugs (1994) [Pubmed]
  12. In vitro extracellular and intracellular activities of clavulanic acid and those of piperacillin and ceftriaxone alone and in combination with tazobactam against clinical isolates of Legionella species. Edelstein, P.H., Edelstein, M.A. Antimicrob. Agents Chemother. (1994) [Pubmed]
  13. In vitro susceptibilities of Capnocytophaga isolates to beta-lactam antibiotics and beta-lactamase inhibitors. Jolivet-Gougeon, A., Buffet, A., Dupuy, C., Sixou, J.L., Bonnaure-Mallet, M., David, S., Cormier, M. Antimicrob. Agents Chemother. (2000) [Pubmed]
  14. Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial. The Severe Generalized Peritonitis Study Group. Dupont, H., Carbon, C., Carlet, J. Antimicrob. Agents Chemother. (2000) [Pubmed]
  15. Kinetics of piperacillin and tazobactam in ventricular cerebrospinal fluid of hydrocephalic patients. Nau, R., Kinzig-Schippers, M., Sörgel, F., Schinschke, S., Rössing, R., Müller, C., Kolenda, H., Prange, H.W. Antimicrob. Agents Chemother. (1997) [Pubmed]
  16. Tazobactam forms a stoichiometric trans-enamine intermediate in the E166A variant of SHV-1 beta-lactamase: 1.63 A crystal structure. Padayatti, P.S., Helfand, M.S., Totir, M.A., Carey, M.P., Hujer, A.M., Carey, P.R., Bonomo, R.A., van den Akker, F. Biochemistry (2004) [Pubmed]
  17. Characterization of OXA-29 from Legionella (Fluoribacter) gormanii: molecular class D beta-lactamase with unusual properties. Franceschini, N., Boschi, L., Pollini, S., Herman, R., Perilli, M., Galleni, M., Frère, J.M., Amicosante, G., Rossolini, G.M. Antimicrob. Agents Chemother. (2001) [Pubmed]
  18. Different ratios of the piperacillin-tazobactam combination for treatment of experimental meningitis due to Klebsiella pneumoniae producing the TEM-3 extended-spectrum beta-lactamase. Leleu, G., Kitzis, M.D., Vallois, J.M., Gutmann, L., Decazes, J.M. Antimicrob. Agents Chemother. (1994) [Pubmed]
  19. Assessment of biliary excretion of piperacillin-tazobactam in humans. Westphal, J.F., Brogard, J.M., Caro-Sampara, F., Adloff, M., Blicklé, J.F., Monteil, H., Jehl, F. Antimicrob. Agents Chemother. (1997) [Pubmed]
  20. Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery. Kinzig, M., Sörgel, F., Brismar, B., Nord, C.E. Antimicrob. Agents Chemother. (1992) [Pubmed]
  21. Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin. Wise, R., Logan, M., Cooper, M., Andrews, J.M. Antimicrob. Agents Chemother. (1991) [Pubmed]
  22. Penetration of piperacillin-tazobactam into cancellous and cortical bone tissues. Incavo, S.J., Ronchetti, P.J., Choi, J.H., Wu, H., Kinzig, M., Sörgel, F. Antimicrob. Agents Chemother. (1994) [Pubmed]
  23. A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group. Eklund, A.E., Nord, C.E. J. Antimicrob. Chemother. (1993) [Pubmed]
  24. Unusual tazobactam-sensitive AmpC beta-lactamase from two Escherichia coli isolates. Babini, G.S., Danel, F., Munro, S.D., Micklesen, P.A., Livermore, D.M. J. Antimicrob. Chemother. (1998) [Pubmed]
  25. Efficacy of beta-lactam and inhibitor combinations in a diffusion chamber model in rabbits. Georgopoulos, A., Buxbaum, A., Graninger, W. J. Antimicrob. Chemother. (1999) [Pubmed]
  26. Characterization of antibiotic resistance plasmids from Bordetella bronchiseptica. Speakman, A.J., Binns, S.H., Osborn, A.M., Corkill, J.E., Kariuki, S., Saunders, J.R., Dawson, S., Gaskell, R.M., Hart, C.A. J. Antimicrob. Chemother. (1997) [Pubmed]
  27. Beta-lactamase inhibitors: relation between kinetic data and in-vitro synergism studies. Cullmann, W. Zentralbl. Bakteriol. (1991) [Pubmed]
  28. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam. Kuck, N.A., Jacobus, N.V., Petersen, P.J., Weiss, W.J., Testa, R.T. Antimicrob. Agents Chemother. (1989) [Pubmed]
  29. beta-Lactamase types amongst Staphylococcus aureus isolates in relation to susceptibility to beta-lactamase inhibitor combinations. Bonfiglio, G., Livermore, D.M. J. Antimicrob. Chemother. (1994) [Pubmed]
  30. SYN-1012: a new beta-lactamase inhibitor of penem skeleton. Phillips, O.A., Czajkowski, D.P., Spevak, P., Singh, M.P., Hanehara-Kunugita, C., Hyodo, A., Micetich, R.G., Maiti, S.N. J. Antibiot. (1997) [Pubmed]
  31. Kinetic analysis of an inhibitor-resistant variant of the OHIO-1 beta-lactamase, an SHV-family class A enzyme. Lin, S., Thomas, M., Shlaes, D.M., Rudin, S.D., Knox, J.R., Anderson, V., Bonomo, R.A. Biochem. J. (1998) [Pubmed]
  32. Inhibition of the SHV-1 beta-lactamase by sulfones: crystallographic observation of two reaction intermediates with tazobactam. Kuzin, A.P., Nukaga, M., Nukaga, Y., Hujer, A., Bonomo, R.A., Knox, J.R. Biochemistry (2001) [Pubmed]
  33. Comparative activity of piperacillin/tazobactam against 5625 isolates from hospitalised patients. Multicentre Study Group. Verbist, L., Verhaegen, J., Wouters, C., Vandenhoven, G. J. Antimicrob. Chemother. (1996) [Pubmed]
WikiGenes - Universities